SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: N/E PATSFAN who wrote (1095)12/4/1999 11:33:00 AM
From: scaram(o)ucheRead Replies (1) | Respond to of 4974
 
NEPF:

Yeah, Novartis. Nope, don't. The key, if there is one, is in "STI". The Ciba designation was "CGP". The Sandoz designation was "SDZ".

Is there a Swiss equivalent of EDGAR?

In any event, maybe this will turn the tide of excitement a bit back from antibodies and other biologicals to small molecules. Sugen is gone, but there's OSIP and others.

I've got a place to look. I'll poke around, but this is soccer playoff weekend, and I should have about 5 minutes free before market open on Monday. <g>

Rick



To: N/E PATSFAN who wrote (1095)12/4/1999 12:57:00 PM
From: scaram(o)ucheRead Replies (2) | Respond to of 4974
 
from an AP article......

Druker, who is to present his findings on Sunday to the American Society of Hematology in
New Orleans, said he has been working for a decade to find that compound. He and
Novartis researchers created the first version six years ago and have been testing and
refining it ever since.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News